The invention relates to the use of erythropoietin (EPO), in particular EPO in a pharmaceutical preparation, for the treatment of traumatized or diseased eyes, in particular the case of endothelial dysfunction or dystrophies of the eye, preferably in connection with mechanical or pathological injuries of the cornea and conditions related thereto, as well as injuries following eye surgery.
